Synovo

Synovo GmbH is a Tübingen-based pharmaceutical discovery services company founded in 2004. With a focus on inflammation and innate immunity, Synovo provides a range of services including medicinal chemistry, pharmacology, cell engineering, histology, in vitro assays, and peptide modification. The company's main pharmacology activities revolve around assays and models for the selection of drug candidates with improved properties of Absorption, Disposition, Metabolism and Elimination (ADME or DMPK). Synovo utilizes human-derived cells, proteins, and systems to ensure the relevance of its data for use in man.

Synovo is actively engaged in projects related to anti-inflammatory and immune suppressive drug optimization, often working with clients from the pharmaceutical industry and partnering with public sector laboratories to enhance its systems and extend its technologies to protein and nucleic acid drugs. Despite being self-sustaining through its service business and consistently profitable, Synovo conducts innovative research in collaboration with partners worldwide, resulting in the development of various drug candidates for immune-oncology applications, inflammatory bowel disease, and infection.

Located in Tübingen, Germany, Synovo GmbH benefits from access to cutting-edge technology, highly skilled staff, and a remarkable location overlooking the Swabian Alps.

Industries: Pharmaceutical

In conclusion, Synovo GmbH, with its comprehensive range of services and profitable business model, presents an enticing opportunity for investment in the pharmaceutical industry. The company's focus on innovative research and collaboration with global partners positions it well for continued success and potential growth in the sector.